NEW YORK, Sept. 24 /PRNewswire/ -- Stephen Simes, chief executive officer of BioSante Pharmaceuticals, Inc. (Amex: BPA) (http://www.biosantepharma.com) will be featured in an exclusive interview with http://www.wallst.net scheduled for September 26 at 10:30 a.m. EDT. The interview will be posted on http://www.wallst.net by 8 p.m. EDT on September 26.
The interview will cover topics including BioSante's market potential, growth initiatives, competitive edge, recent news, and milestones for which investors should watch.
To hear the interview in its entirety, visit http://www.wallst.net, and click on "Interviews." The interview can be accessed either by locating the company's ticker symbol under the appropriate exchange at the top of the "Interviews" section or by entering the company's ticker symbol in the Search Archive window on the right-hand column of the "Interviews" section once it is posted.
About BioSante Pharmaceuticals, Inc.
BioSante is developing a pipeline of hormone therapy products to treat
both men and women. These hormone therapy products are gel formulations for
transdermal administration that deliver bioidentical estradiol and
testosterone. BioSante's lead products include Elestrin(TM) (estradiol gel)
developed through FDA approval by BioSante indicated for the treatment of
moderate-to-severe vasomotor symptoms associated with menopause, and
LibiGel(R) (transdermal testosterone gel) in Phase III clinical development
by BioSante for the treatment of female sexual dysfunction (
|SOURCE Financial Filings Corp.|
Copyright©2007 PR Newswire.
All rights reserved